Bringing the Oncology Community Together

Dr. Edith Perez Discusses Her Ongoing Research

Edith A. Perez, MD
Published Online: Wednesday, April 27, 2011


Edith A. Perez, MD, director of the Breast Program and professor of medicine at the Mayo Clinic discusses her ongoing research.
Related Articles
After years of varying decisions by lower courts regarding the patents held on a test for genetic mutations associated with breast cancer, the US Supreme Court has ruled that a segment of DNA in isolation is a natural product and not eligible for patent protection.
In this segment, the panelists discuss the combination of novel agents with hormonal therapies. To begin the conversation, the BOLERO-2 trial is explored, which looked at the mTOR inhibitor everolimus as a treatment for patients with metastatic breast cancer.
Although recent findings suggest some patients with HER2-negative breast cancer would benefit from therapies directed against overexpression of the protein, two leading oncologists do not see an immediate impact on clinical practice as further validation is needed.
Most Popular Right Now
Physicians' Education Resource
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedHC
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2013
Intellisphere, LLC. All Rights Reserved.